PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Common Stock (PACB)

CUSIP: 69404D108

Q1 2021 13F Holders as of 31 Mar 2021

Security type / class
Equity / Common Stock
Total 13F shares
164,192,829
Total 13F value
$5,468,916,669
Holder snapshot 6 visible 7 signals
Share change
-9,551,620
Put/Call ratio
49%
SEC-reported price per share
$33.31
Number of holders
249
Value change
-$280,136,379
Number of buys
123
Open additional details 1 more signal available
Number of sells
77
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
301,979,157

Security key

69404D108

Report period

Q1 2021

Institutions

249

Top holders

10

PACB full security history Ownership snapshot Full 13F holder table Newer quarter: Q2 2021 Previous quarter: Q4 2020 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC filings PACIFIC BIOSCIENCES OF CALIFORNIA, INC. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of PACB - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ARK Investment Management...
Disclosed value leader
ARK Investment Management...
Comparable rows
15/15
Latest evidence
31 Dec 2020
13F Lead comparable stake: 9.4% Showing 1-6 of 15 holder rows.

Quick read

ARK Investment Management LLC leads the comparable SEC ownership view at 9.4%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ARK Investment Management LLC's linked filing trail.
Comparable ownership Top 5
ARK Investment Management LLC 9.4%
BlackRock Finance, Inc. 5%
VANGUARD GROUP INC 4.7%
Jackson Square Partners, LLC 4.5%
Capital International Investors 3.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ARK Investment Management LLC
13F
Company
13F
9.4%
$739,410,000
28,504,629 shares
 — 31 Dec 2020
BlackRock Finance, Inc.
13F
Company
13F
5%
$392,094,000
15,115,490 shares
 — 31 Dec 2020
VANGUARD GROUP INC
13F
Company
13F
4.7%
$371,468,000
14,320,299 shares
 — 31 Dec 2020
Jackson Square Partners, LLC
13F
Company
13F
4.5%
$349,526,000
13,474,438 shares
 — 31 Dec 2020
Capital International Investors
13F
Company
13F
3.2%
$254,420,000
9,808,026 shares
 — 31 Dec 2020
SB Management Ltd
13F
Company
13F
3%
$238,434,000
9,191,755 shares
 — 31 Dec 2020
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
249
Shares
164,192,829
Rows available
249
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2021 vs Q4 2020 Across Filers

Q4 2020 holders
149
Q1 2021 holders
249
Holder diff
100
Investor Q4 2020 Shares Q1 2021 Shares Share Diff Share Chg % Q4 2020 value Q1 2021 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .